Praecis to meet with FDA in September

PRCS said that a meeting for its NDA for Plenaxis abarelix depot LHRH/GnRH antagonist to treat prostate cancer has been scheduled for Sept. 10. In June, PRCS and partner Amgen (AMGN) received a letter...